REFERENCES
- Barlow , R. E. , Proschan , F. ( 1981 ). Statistical Theory of Reliability and Life Testing. Silver Spring , MD : TO BEGIN WITH , pp. 63 – 69 .
- Beyer , W. H. ( 1968 ). CRC Handbook of Tables for Probability and Statistics . 2nd ed. Cleveland , Ohio : CRC , pp. 238 – 239 .
- Committee for Proprietary Medicinal Products (CPMP) . ( 1997 ). Points to Consider on Hormone Replacement Therapy . http://www.emea.eu.int/pdfs/human/ewp/002197en.pdf
- Leemis , L. M. , Trivedi , K. S. ( 1996 ). A comparison of approximate interval estimators for the Bernoulli parameter . Am. Stat. 50 ( 1 ): 63 – 68 .
- Pickar , J. H. , Yeh , I. T. , Wheeler , J. E. , Cunnane , M. F. , Speroff , L. ( 2001 ). Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate . Fertil. Steril. 76 ( 1 ): 25 – 31 . [CSA] [CROSSREF]
- Rothman , K. J. ( 1986 ). Modern Epidemiology. Boston : Little Brown , pp. 23 – 25 , 153 – 176 .
- Sahai , H. , Khurshid , A. ( 1996 ). Statistics in Epidemiology . New York : CRC Press .
- Shulman , L. P. , Yankov , V. , Uhl , K. ( 2002 ). Safety and efficacy of a continuous once-a-week 17 β-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: The results of two multicenter, double-blind, randomized, controlled trials . Menopause 9 ( 3 ): 195 – 207 . [CSA] [CROSSREF]
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research . ( 2003 ). Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms–-Recommendations for Clinical Evaluation, Draft Guidance . http://www.fda.gov/cder/guidance/5412dft.doc
- Writing Group for the Women's Health Initiative Investigators . ( 2002 ). Risks and benefits of estrogen plus progestin in healthy postmenopausal women . JAMA. 288 ( 3 ): 321 – 333 . [CROSSREF]